Nerinetide
Also known as: NA-1, Nerinetide, Neuroprotective peptide NA‑1, PSD-95 inhibitor peptide, Tat-NR2B9c
Source Nerinetide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Nerinetide (NA-1) is a synthetic peptide designed for acute neuroprotection in ischemic stroke and traumatic brain injury by blocking NMDA‑receptor‑mediated excitotoxicity.
Mechanism of Action
Disrupts the interaction between NMDA receptor subunit GluN2B and PSD-95, reducing excitotoxic calcium influx and downstream neurotoxic signaling.
Routes of Administration
Goals & Uses
- Prevention of delayed neuronal death post-ischemiaNeuroprotectionModerate
- Reduction of infarct volume after endovascular thrombectomyNeurology / InterventionalModerate
- Acute ischemic strokeNeuroprotectionModerate
- Neuroprotection in acute ischemic strokeNeurology / StrokeModerate
- Traumatic brain injuryNeuroprotectionLow
Contraindications
- Severe renal impairment (eGFR <30 mL/min)RenalModerate
- Known hypersensitivity to nerinetide or any componentAllergyHigh
Adverse Effects
- Overall adverse event profile similar to placeboGeneralCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularUncommonLow blood pressure
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- Alteplase (tPA)Low
Population Constraints
- Severe renal or hepatic impairmentOrgan FunctionRelative
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pediatrics (<18 y)AgeAbsolute
Regulatory Status
- European UnionInvestigationalUnder EMA assessment; not approved.
- United StatesInvestigationalPhase 3 clinical trial (ESCAPE‑NA1).
- United KingdomInvestigationalMHRA classifies as clinical trial material.
Not approved in any major jurisdiction; currently in Phase 3 clinical development for acute ischemic stroke (ESCAPE‑NA1) and exploratory trials for TBI.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Nerinetide?
Nerinetide (NA-1) is a synthetic peptide designed for acute neuroprotection in ischemic stroke and traumatic brain injury by blocking NMDA‑receptor‑mediated excitotoxicity.
What is Nerinetide used for?
Nerinetide is educationally associated with: Prevention of delayed neuronal death post-ischemia, Reduction of infarct volume after endovascular thrombectomy, Acute ischemic stroke, Neuroprotection in acute ischemic stroke, Traumatic brain injury. Educational only — not medical advice.
How is Nerinetide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Nerinetide?
Reported adverse effects include: Overall adverse event profile similar to placebo, Headache, Hypotension, Nausea, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Nerinetide?
Recorded contraindications: Severe renal impairment (eGFR <30 mL/min), Known hypersensitivity to nerinetide or any component. Consult a qualified clinician before use.